title: Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation.
abstract: For an effective CD8+ cytotoxic T cell response to occur during infection, MHC class I molecules must be loaded with antigenic peptides in the endoplasmic reticulum. The cytosolic factor responsible for peptide generation is believed to be the proteasome, with the TAP heterodimer mediating peptide transport into the endoplasmic reticulum. However, the rate-determining step(s) in this intracellular pathway of Ag presentation is currently unresolved. The availability of a specific and irreversible proteasome inhibitor called lactacystin has enabled us to determine the amount of proteasomes required for the peptide loading of MHC class I molecules in four cell types. In the absence of the IFN-gamma-inducible proteasome subunits LMP2 and LMP7, the trypsin-like (but not the chymotrypsin-like) activity of the proteasome is directly related to MHC class I peptide loading. However, IFN-gamma stimulation or assimilation of catalytic LMP2 and LMP7 subunits into proteasomes causes both chymotrypsin- and trypsin-like activities of the proteasome to become limiting for the loading of class I molecules. Our data suggest that upon full IFN-gamma stimulation, peptide supply by the proteasome is the limiting step in the assembly of MHC class I polypeptides. This mechanism may enable the cell to prevent competition between novel Ags and the pool of endogenous proteins for binding to MHC class I molecules.
authors.affiliation: Division Cellular Biochemistry, The Netherlands Cancer Institute, Amsterdam.
authors.forename: A M
authors.initials: AM
authors.lastname: Benham
authors.forename: J J
authors.initials: JJ
authors.lastname: Neefjes
mesh_terms: D002461:Cell Line, Transformed; D002918:Chymotrypsin / Q000378:metabolism / Q000502:physiology; D003546:Cysteine Endopeptidases / Q000378:metabolism* / Q000502:physiology; D006680:HLA Antigens / Q000378:metabolism*; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008545:Melanoma / Q000201:enzymology / Q000276:immunology; D009097:Multienzyme Complexes / Q000378:metabolism* / Q000502:physiology; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000201:enzymology* / Q000276:immunology; D014357:Trypsin / Q000378:metabolism / Q000502:physiology; D014407:Tumor Cells, Cultured; D014763:Viral Matrix Proteins / Q000172:deficiency
chemical_list: C037662:EBV-associated membrane antigen, Epstein-Barr virus; D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D009097:Multienzyme Complexes; D011506:Proteins; D014763:Viral Matrix Proteins; D007371:Interferon-gamma; D002918:Chymotrypsin; D014357:Trypsin; D003546:Cysteine Endopeptidases; C077436:LMP7 protein; D046988:Proteasome Endopeptidase Complex